Lv71
4980 积分 2022-04-25 加入
学术
Anti-PD-L1 antibody ASC22 in combination with a histone deacetylase inhibitor chidamide as a “shock and kill” strategy for ART-free virological control: a phase II single-arm study
1小时前
待确认
A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B: Is cirrhosis driving the performance?
9天前
已完结
Hepatocellular Carcinoma Patients as an Ideal Study Population for Immune Checkpoint Inhibitors in Hepatitis B
9天前
已完结
Single-cell RNA sequencing reveals the immunoregulatory roles of PegIFN-α in patients with chronic hepatitis B
22天前
已完结
PD-L1 at the crossroad between RNA metabolism and immunosuppression
26天前
已完结
COVID-19 Is a Coronary Artery Disease Risk Equivalent and Exhibits a Genetic Interaction With ABO Blood Type
1个月前
已完结
[HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)-ide analog: new switch study]
1个月前
已完结
Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy
1个月前
已完结
Clinical characteristics and immunogenicity after Omicron breakthrough infection in patients with chronic hepatitis B infection: A longitudinal observational study
2个月前
已完结
Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy
3个月前
已完结
皖公网安备34019202002308
